NEW MJ NEWS

AbbVie to Host First-Quarter 2023 Earnings Conference Call

AbbVie (NYSE: ABBV) will announce its first-quarter 2023 financial results on Thursday, April 27, 2023, before the market opens. AbbVie will host a live webcast of the earnings conference call at 8 a.m. CT. It will be accessible through AbbVie’s Investor Relations website investors.abbvie.com. An archived edition of the session will be available later that day.

About AbbVie

AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, YouTube and LinkedIn.

View original content:https://www.prnewswire.com/news-releases/abbvie-to-host-first-quarter-2023-earnings-conference-call-301788964.html

SOURCE AbbVie


MAPH Enterprises, LLC | (305) 414-0128 | 1501 Venera Ave, Coral Gables, FL 33146 | new@marijuanastocks.com
Leave a Reply

Your email address will not be published. Required fields are marked *

You May Also Like

Charlotte’s Web Holdings Inc. (CWBHF) Announces Appointment of Former Ben & Jerry’s CEO, Matthew E. McCarthy

Charlotte’s Web Holdings Inc. Announces Appointment of former Ben & Jerry’s CEO,…

$FITX Announces a CEN Biotech Inc. Update

Creative Edge Nutrition, Inc. Announces a CEN Biotech Inc. Update  Giddy Up…

Innovative Industrial Properties, Inc. (IIPR) Prices Public Offering of 2,967,799 Shares of Common Stock

Innovative Industrial Properties Prices Public Offering of 2,967,799 Shares of Common Stock…

Organigram Holdings Inc. (OGRMF) Announces Letter of Intent for Strategic Investment in Hyasynth Biologicals Inc.

Organigram Announces Letter of Intent for Strategic Investment in Hyasynth Biologicals Inc.…